DoxorubicinAntibiotics, AntineoplasticInduction ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsTaxoidsAntineoplastic AgentsCisplatinCombined Modality TherapyCell Line, TumorTreatment OutcomeDrug Resistance, NeoplasmChemotherapy, AdjuvantRemission InductionPaclitaxelApoptosisBreast NeoplasmsCaspase 12Disease-Free SurvivalCyclophosphamideTumor Suppressor Protein p53Drug Administration ScheduleSurvival AnalysisNeoadjuvant TherapyNeoplasm StagingSurvival RateLung NeoplasmsEtoposideFluorouracilHead and Neck NeoplasmsAntineoplastic Agents, PhytogenicVincristineCarcinoma, Squamous CellCardiomyopathiesDaunorubicinCytarabineCarboplatinMitochondria, HeartPrognosisVinblastineIfosfamideDNA DamageCarcinoma, Non-Small-Cell LungDeoxycytidineLeukemia, Myeloid, AcuteDose-Response Relationship, DrugNeoplasm MetastasisTumor Markers, BiologicalRNA, Small InterferingNeoplasm Recurrence, LocalMyocardiumSignal TransductionRNA, MessengerHeartGene Expression Regulation, NeoplasticTime FactorsNeutropeniaMethotrexateAdenocarcinomaRadiotherapy, AdjuvantBleomycinFollow-Up StudiesEnzyme InductionTumor BurdenKaplan-Meier EstimateChemoradiotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaMitoxantroneInfusions, IntravenousRadiotherapyNeoplasmsGranulocyte Colony-Stimulating FactorRadiotherapy DosageSalvage TherapyIdarubicinBone NeoplasmsAnthracyclinesHypopharyngeal NeoplasmsProspective StudiesTumor Necrosis Factor-alphaAntimetabolites, AntineoplasticLeukopeniaDisease ProgressionLaryngectomyTransplantation, AutologousP-GlycoproteinLeukemia, MyeloidNasopharyngeal NeoplasmsBrain NeoplasmsPrednisoneAntibodies, MonoclonalEpirubicinXenograft Model Antitumor AssaysOvarian NeoplasmsTesticular NeoplasmsMelphalanBridged CompoundsAntibodies, Monoclonal, HumanizedMaximum Tolerated DoseLymphatic MetastasisOrganoplatinum Compounds